Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

Authors

Erdogan Taskesen

Published

December 22, 2010

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

Blood

Topics

DOI

10.1182/blood-2010-09-307280

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

Authors

Erdogan Taskesen

Published

December 22, 2010

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

Blood

Topics

DOI

10.1182/blood-2010-09-307280

Paper

Paper

Paper

Paper

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

Supporters

Journal

Topics

DOI

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

Supporters

Journal

Topics

DOI